The initial focus for the treatment of SMA was on motor neurons located in the spinal cord, and pharmaceuticals were created to address the deficiency of SMN in these neurons (Mercuri et al., 2020). The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.